Abstract
We report two cases of type 1 diabetes mellitus (T1DM) which developed after interferon (IFN) therapy for chronic hepatitis C. The patients had experienced abrupt hyperglycemia with positive anti-glutamic acid decarboxylase antibodies, resulting in initiation of insulin therapy. In one case, insulin therapy could be discontinued because endogenous insulin secretion was preserved at the onset and pancreatic beta cell function was recovered thereafter. In the other case with Hashimoto's thyroiditis and Sjögren's syndrome, continuation of insulin therapy was necessary because blood glucose levels were unstably controlled. Lasting autoimmunity superior to immunosuppressive mechanism may be associated with distinct clinical courses in these cases.
MeSH terms
-
Aged
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use
-
Blood Glucose / metabolism
-
Diabetes Mellitus, Type 1 / chemically induced*
-
Diabetes Mellitus, Type 1 / diagnosis
-
Diabetes Mellitus, Type 1 / drug therapy
-
Female
-
Hashimoto Disease / blood
-
Hashimoto Disease / immunology
-
Hepatitis C, Chronic / drug therapy*
-
Humans
-
Hypoglycemic Agents / therapeutic use
-
Insulin / therapeutic use
-
Interferon alpha-2
-
Interferon-alpha / adverse effects*
-
Interferon-alpha / therapeutic use*
-
Middle Aged
-
Polyethylene Glycols / adverse effects*
-
Polyethylene Glycols / therapeutic use*
-
Recombinant Proteins
-
Sjogren's Syndrome / blood
-
Sjogren's Syndrome / immunology
Substances
-
Antiviral Agents
-
Blood Glucose
-
Hypoglycemic Agents
-
Insulin
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Polyethylene Glycols
-
peginterferon alfa-2b
-
peginterferon alfa-2a